Literature DB >> 3913425

[Electroencephalography and psychometric measurements during the treatment of cerebral insufficiency with nicergoline and dihydroergotamine mesylate].

J E Kugler, B C Meurer-Krüll.   

Abstract

28 persons with an average age of 55 years were treated for 180 days with daily doses of 30 mg nicergoline (Sermion) and 28 persons of a comparable age were treated for the same length of time with 6 mg dihydroergotamine mesilate (DHETM) daily. Unwanted reactions occurred to a small degree in both treatment groups; they were mostly of a temporary nature and did not impede continuation of treatment. The results of the psychometric tests showed an increase in performance in both groups which was partly caused by the learning effect in repeated tests. The answers given by the patients concerning subjective changes in symptoms and general condition showed no significant differences between the two treatment groups. This leads to the assumption that both compounds have a similar effect. The analyses of the EEG activities showed a characteristic increase in the fast EEG activities after the application of nicergoline. This would indicate that there are differences in the pharmacodynamics in comparison with DHETM.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3913425

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  4 in total

Review 1.  Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment.

Authors:  M Fioravanti; L Flicker
Journal:  Cochrane Database Syst Rev       Date:  2001

Review 2.  Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline.

Authors:  A N Wadworth; P Chrisp
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

Review 3.  A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline.

Authors:  Mario Fioravanti; Taku Nakashima; Jun Xu; Amit Garg
Journal:  BMJ Open       Date:  2014-07-30       Impact factor: 2.692

Review 4.  Safety of nicergoline as an agent for management of cognitive function disorders.

Authors:  Bernd Saletu; Amit Garg; Ahsan Shoeb
Journal:  Biomed Res Int       Date:  2014-08-28       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.